Study Details
Design, interventions, and primary outcomes
About This Study
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
Design
Interventions / Regimen
- Drug: Simvastatin combined with Amlodipine besylate — 6-month treatment of Simvastatin combined with Amlodipine besylate
- Drug: Simvastatin combined with Spironolactone and Amlodipine besylate. — 6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
- Drug: Amlodipine besylate combined Spironolactone — 6-month treatment of Amlodipine besylate combined with Spironolactone
Primary Outcomes
- changes in plasma aldosterone levels (6 month)
- changes in 24-hour urinary aldosterone levels (6 month)
Phase: PHASE4
Status: Recruiting
Start Date: 2024-09-10
Completion: 2026-09-30
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
- Drug: Simvastatin combined with Amlodipine besylate — 6-month treatment of Simvastatin combined with Amlodipine besylate
- Drug: Simvastatin combined with Spironolactone and Amlodipine besylate. — 6-month treatment of Simvastatin combined with Spironolactone and Amlodipine besylate.
- Drug: Amlodipine besylate combined Spironolactone — 6-month treatment of Amlodipine besylate combined with Spironolactone